M&A / Deals Gilead outlays $5bn to acquire ADC specialist Tubulis Pharmaceutical TechnologySixteen months after partnering with Tubulis, Gilead has decided to acquire the biotech and its portfolio of ADCs.M&A / DealsRead full story pharminent April 7, 2026 (Last updated: April 7, 2026) Pharmaceutical Technology Sixteen months after partnering with Tubulis, Gilead has decided to acquire the biotech and its portfolio of ADCs. M&A / DealsRead full story Post navigation Previous: Gilead Swallows Another Partner, Paying up to $5B for ADC Specialist TubulisNext: Gilead continues M&A surge with $3.1B deal for ADC specialist Tubulis Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
